Literature DB >> 9323493

Changes in levels of expression of p53 and the product of the bcl-2 in lines of gastric cancer cells during cisplatin-induced apoptosis.

M Ikeguchi1, S Tatebe, N Kaibara, H Ito.   

Abstract

Five lines (MKN-28, MKN-45, MKN-74, KATO-III, and HSC-39) of human gastric carcinoma cells were treated with 1 microgram/ml cisplatin for 12, 24, 36, 48, and 72 h. Apoptotic indices (percentages of apoptotic cells) were analyzed at each time point. After incubation with cisplatin, apoptotic cells were detected more frequently among MKN-45 and MKN-74 cells with a wild-type gene for p53 and without expression of the bcl-2 protein than among HSC-39, MKN-28, and KATO-III cells with a mutation or complete deletion of the gene for p53 and with overexpression of the bcl-2 protein. The levels of p53 protein increased after treatment with cisplatin in MKN-74 cells. However, levels of bcl-2 protein were reduced in KATO-III after treatment with cisplatin. Thus, p53 status and the expression of bcl-2 by tumor cells might be good indicators of sensitivity to chemotherapy for patients with gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9323493     DOI: 10.1159/000129549

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  10 in total

1.  Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer.

Authors:  A G Xu; S G Li; J H Liu; A H Gan
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.

Authors:  Shunichi Tsujitani; Hiroaki Saito; Toshiro Wakatsuki; Masahide Ikeguchi; Ken Shirabe; Masaru Morita; Yoshihiro Kakeji; Tokujiro Yano; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

3.  Prognostic relevance of p53 and bcl-2 immunoreactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections?

Authors:  R Kopp; J Diebold; I Dreier; C Cramer; J Glas; G Baretton; K W Jauch
Journal:  Surg Endosc       Date:  2005-09-21       Impact factor: 4.584

4.  Targeting molecular pathways with camptothecin as novel therapy for gastric cancer.

Authors:  D A Litvak; H T Papaconstantinou; B M Evers; C M Townsend
Journal:  J Gastrointest Surg       Date:  1999 Nov-Dec       Impact factor: 3.452

5.  BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy.

Authors:  H Strik; M Deininger; J Streffer; E Grote; J Wickboldt; J Dichgans; M Weller; R Meyermann
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

6.  Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.

Authors:  F Bataille; P Rümmele; W Dietmaier; D Gaag; F Klebl; A Reichle; P Wild; F Hofstädter; A Hartmann
Journal:  Mol Pathol       Date:  2003-10

7.  Growth-inhibiting and apoptosis-inducing effects of Tanshinone II A on human gastric carcinoma cells.

Authors:  Xiarong Dong; Jihua Dong; Gang Peng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

8.  Antagonizing canonical Wnt signaling pathway by recombinant human sFRP4 purified from E. coli and its implications in cancer therapy.

Authors:  Archita Ghoshal; Siddhartha Sankar Ghosh
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

9.  Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer.

Authors:  S Kamoshida; M Suzuki; R Shimomura; Y Sakurai; Y Komori; I Uyama; Y Tsutsumi
Journal:  Br J Cancer       Date:  2007-01-09       Impact factor: 7.640

10.  Urushiol Induces Apoptosis via a p53-dependent Pathway in Human Gastric Cancer Cells.

Authors:  Seaho Kim; Dong Hwan Kim; Sun Hwa Lee; Min Jeong Kim; Jeong-Hyun Yoon; Hae Young Chung; Chun Soo Na; Nam Deuk Kim
Journal:  J Cancer Prev       Date:  2013-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.